Related Experiment Videos

Overexpression of KIT in chromophobe renal cell carcinoma

Ken Yamazaki1, Michiie Sakamoto, Tsutomu Ohta

  • 1Cancer Genomics Division, National Cancer Center Research Institute, Tokyo, Japan.

Oncogene
|February 14, 2003
PubMed

Insights

This study identified unique gene expression profiles for different renal cell carcinoma (RCC) subtypes. The KIT oncogene was specifically upregulated in chromophobe RCC, suggesting it as a potential diagnostic marker and therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Renal cell carcinoma (RCC) is a heterogeneous disease with distinct histological subtypes.
  • Understanding subtype-specific molecular alterations is crucial for diagnosis and treatment.
  • Gene expression profiling offers a comprehensive approach to identify such alterations.

Purpose of the Study:

  • To identify unique gene-expression profiles for conventional, papillary, and chromophobe subtypes of renal cell carcinoma (RCC).
  • To investigate the potential of specific genes as diagnostic markers for RCC subtypes.
  • To explore novel therapeutic targets for specific RCC types.

Main Methods:

  • Analysis of gene-expression profiles from 15 surgical specimens of RCC using high-density oligonucleotide arrays.
  • Identification of genes specifically upregulated in each RCC histological subtype.
  • Immunohistochemical validation of KIT gene product expression in RCC tissues.

Main Results:

  • Out of approximately 12,000 genes analyzed, 67 were specifically upregulated in each RCC histological type.
  • The oncogene KIT was found to be specifically upregulated in chromophobe RCC.
  • KIT gene product was detected on the cell membrane of chromophobe RCC in all cases, with minimal expression in other RCC types and normal kidney tissue.

Conclusions:

  • Each histological subtype of RCC exhibits a unique gene-expression profile.
  • KIT represents a potential diagnostic marker for chromophobe RCC.
  • KIT overexpression may contribute to tumor growth, positioning KIT as a potential therapeutic target for chromophobe RCC.

Related Concept Videos